The vasodepressor function of the kidney: Further characterization of medullipin and a second hormone designated angiolysin

Hypertension Research

Volumn 29, Issue 7, 2006, Pages 533-544

  Glodny, Bernhard ^a,c   Pauli, Guido F ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Angiolysin; Blood pressure; Hypertension; Medullipin; Renal function

Indexed keywords

ACETYLCHOLINE; ANGIOLYSIN; ANTIHYPERTENSIVE AGENT; MEDULLIPIN 1; NITROPRUSSIDE SODIUM; NORADRENALIN; POTASSIUM; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY; COW; DOSE RESPONSE; DRUG POTENCY; HYPERTENSION; IN VIVO STUDY; KIDNEY FUNCTION; MOUSE; NONHUMAN; RAT; SHEEP; SPONTANEOUSLY HYPERTENSIVE RAT; SWINE; VASCULAR RING; VASOCONSTRICTION; VASODILATATION;

ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEART RATE; HORMONES; KIDNEY; KIDNEY MEDULLA; LIPIDS; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PARTICLE SIZE; PROSTAGLANDINS; RATS; RATS, INBRED SHR; RATS, WISTAR; RENAL CIRCULATION; SWINE;

EID: 33748557764     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.533     Document Type: Article

References (25)

1. Muirhead EE, Stirman JA, Jones F: Renal autoexplantation and protection against renoprival hypertensive cardiovascular disease and hemolysis. J Clin Invest 1960; 39: 266-281.
2. Daniels EG, Hinman JW, Leach BE, Muirhead EE: Identification of prostaglandin E2 as the principal vasodepressor lipid of rabbit renal medulla. Nature 1967; 215: 1298-1299.
3. Lee JB, Crowshaw K, Takman BH, Attrep KA, Gougoutas JZ: The identification of prostaglandins E2, F2a and A2 from rabbit kidney medulla. Biochem J 1967; 105: 1251-1261.
4. Muirhead EE, Brooks B, Byers LW: Biologic differences between vasodilator prostaglandins and medullipin I. Am J Med Sci 1992; 303: 86-89.
5. Muirhead EE, Folkow B, Byers LW, et al: Cardiovascular effects of antihypertensive polar and neutral renomedullary lipids. Hypertension 1983; 5: 1112-1118.
6. Muirhead EE: Depressor functions of the kidney. Semin Nephrol 1983; 3: 14-29.
7. Prewitt RL, Leach BE, Byers LW, Brooks B, Lands WEM, Muirhead EE: Antihypertensive polar renomedullary lipid, a semisynthetic vasodilator. Hypertension 1979; 1: 299-308.
8. Brooks B, Byers LW, Muirhead EE, et al: Purification of class I medullipins from the venous effluent of isolated normal kidneys perfused under high pressure with saline. Blood Press 1994; 3: 407-417.
9. Kusuoka H, Hoffman JI: Advice on statistical analysis for circulation research. Circ Res 2002; 91: 662-671.
10. Glodny B, Pauli G: Medullopressin: a new pressor activity from the renal medulla. Hypertens Res 2005; 28: 827-836.
11. Vincent S, Sheen W: The effects of intravascular injections of extracts of animal tissues. J Physiol 1903; 30: 242-265.
12. Thauer, R: Die Wirkung von Nierenpreβsäften und -extrakten auf den Blutdruck von Versuchstieren. Zentralbl Inn Med 1933; 54: 2-15.
13. Grollman A, Muirhead EE, Vanatta J: Role of the kidney in pathogenesis of hypertension as determined by a study of the effects of bilateral nephrectomy and other experimental procedures on the blood pressure of the dog. Am J Physiol 1949; 157: 21-30.
14. Page IH, Helmer OM, Kohlstaedt KG, Kempf GF, Gambill WD, Taylor RD: The blood pressure reducing property of extracts of kidneys in hypertensive patients and animals. Ann Intern Med 1941; 15: 347-389.
15. Muirhead EE: The renomedullary system of blood pressure control. Am J Med Sci 1988; 295: 231-233.
16. Muirhead EE, Byers LW, Desiderio DM Jr, et al: Derivation of antihypertensive neutral renomedullary lipid from renal venous effluent. J Lab Clin Med 1982; 99: 64-75.
17. Kobayashi Y, Nakayama T, Sato N, Izumi Y, Kokubun S, Soma M: Haplotype-based case-control study revealing an association between the adrenomedullin gene and proteinuria in subjects with essential hypertension. Hypertens Res 2005; 28: 229-236.
18. Sakuma Y, Nonoguchi H, Takayama M, et al: Differential effects of hyperosmolatity on Na-K-ATPase and vasopressin-dependent cAMP generation in the medullary thick ascending limb and outer medullary collecting duct. Hypertens Res 2005; 28: 671-679.
19. Tamaki S, Nakamura Y, Tabara Y, et al: Combined analysis of polymorphisms in angiotensinogen and adducin genes and their effects on hypertension in a Japanese sample: the Shigaraki Study. Hypertens Res 2005; 28: 645-650.
20. Takahashi H: Endogenous digitalislike factor: an update. Hypertens Res 2000; 23 (Suppl): S1-S5.
21. Brooks B, Byers LW, Muirhead EE, et al: Purification of class I medullipins from the venous effluent of isolated normal kidneys perfused under high pressure with saline. Blood Press 1994; 3: 407-417.
22. Muirhead EE, Brooks B, Byers LW: Biologic diffirences between vasodilator prostaglandins and medullipin 1. Am J Med Sci 1992; 303: 86-89.
23. Eloff JN: Quantification the bioactivity of plant extracts during screening and bioassay guided fractionation. Phytomedicine 2004; 11: 370-371.
24. Koehn FE, Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-220.
25. Phillipson JD: A matter of some sensitivity. Phytochemistry 1995; 38: 1319-1343.